← All calls
biotechActive

FDA decision (PDUFA) — PRAX relutrigine

Will the FDA approve relutrigine (Praxis Precision Medicines, PRAX) for developmental and epileptic encephalopathies on or before 2026-12-31?

no liveness subject (nothing to death-check)
EHIQ
50%
Market
—
gap vs market
—
—

Thesis

AUTO-SOURCED from the FDA catalyst calendar. NEEDS CALIBRATION before it goes to subscribers: set the EHIQ probability from endpoint quality (hard vs surrogate), trial design (RCT vs single-arm), and any prior CRL, then set digest_excluded=false. Placeholder prob 0.50 = max uncertainty.
Opened
August 13, 2026
Expected resolution
December 31, 2026

Get an alert the moment this call resolves.

Each published EHIQ call carries a resolution date; when it resolves, the verdict is posted here. Subscribe free and we email you when this one grades, plus the weekly divergence leaderboard.

Free forever. Unsubscribe anytime. No spam.